key: cord-0860110-ms8la4s0 authors: Buttery, Jim P. title: Developing standard safety outcomes for COVID-19 vaccines date: 2021-03-12 journal: Vaccine DOI: 10.1016/j.vaccine.2021.03.004 sha: 74aef9d3cb3608f7c452636a4f79104320028863 doc_id: 860110 cord_uid: ms8la4s0 nan approaches. The unprecedented pace of development and implementation is broadly considered the best hope in reducing the human, social and economic devastation of COVID- 19 . However, this welcome speed brings its own challenges. In an era where vaccine hesitancy is a major threat to public health, and confidence in vaccines is linked to perception of vaccine safety, we are trialling and introducing different vaccine designs and regimens, in a myriad of settings. (1) (2) (3) This is in conjunction with reduced times for trial follow-up postimmunisation and the use of post-implementation safety surveillance programs to monitor real-world safety. Never has it been so important to know that potential adverse events following immunisation (AEFI) are being consistently described and defined between different trials, nations, and levels of health care delivery. Achieving this consistency allows an "apples with apples" comparison, providing confidence AEFIs mean the same in all settings. (4) (5) (6) This issue contains papers that propose international consensus case definitions for three important adverse events of special interest (AESI) for COVID-19 vaccines. These are Vaccine Associated Enhanced Disease (VAED), Adult Respiratory Distress Syndrome (ARDS), and Multisystem Inflammatory Syndrome in Children and Adults (MIS-C/A). (7) (8) (9) All remain potential AEFI that may be observed following COVID-19 vaccination, despite no reported cases to date in clinical trials. All revolve around the theoretical possibility that COVID-19 vaccination may predispose some individuals to a more severe manifestation of SARS-CoV-2 infection than if they had never been vaccinated. These concerns are based upon historical lessons, and experience from early non-SARS-CoV-2 coronavirus vaccines in animal models.(10) Lessons learned were incorporated into the design and safety testing of current COVID-19 vaccine candidates. VAED was first observed following randomised trials of an inactivated respiratory syncytial virus (RSV) vaccine more than 5 decades ago.(10-13) These sobering human trials resulted in pediatric RSV vaccine recipients who were seronegative prior to vaccination developing more severe disease when they subsequently experienced natural RSV infection. Two children died from RSV disease. Since then, clinical evidence of VAED has been observed in some recipients following an inactivated measles vaccine, a live-recombinant tetravalent dengue vaccine, and histologic evidence in animal models following SARS-CoV-1 and (1, 2) The VAED case definition will be critical to ensure that potentially severe episodes observed in varying settings can be potentially combined to maximise the chance of detecting or refuting VAED as a real concern for multitude of COVID-19 vaccines of differing designs. These include novel designs for human vaccinology, such as the mRNA vaccines already implemented. (18) ARDS, the most common serious complication of COVID-19 disease, will also continue to occur due to non-SARS-CoV-2 causes, including in vaccinated individuals. Although widely utilised case definitions exist already for ARDS and MISC-C, the need to capture and categorise as many potential AEFI cases as possible renders the Brighton Collaboration approach incorporating levels of confidence necessary. This will maximise the chance, across geographic settings where COVID-19 vaccines are being utilized, to ascertain and report these potential AEFI. This is vitally important, both to protect populations where vaccines are being implemented, and to maximise confidence that despite offering overwhelming benefit, risks are being looked for comprehensively. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study The association between vaccination confidence, vaccination behavior, and willingness to recommend vaccines among Finnish healthcare workers Looking beyond COVID-19 vaccine phase 3 trials The Brighton Collaboration: enhancing comparability of vaccine safety data Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation Vaccine-associated Enhanced Disease: Case Definition and Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data Acute Respiratory Distress Syndrome (ARDS) as an Adverse Event Following Immunization: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data Multisystem Inflammatory Syndrome in Children and Adults (MIS-C/A): Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data Rapid COVID-19 vaccine development Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, longterm follow-up of the phase 2b HVTN 503/Phambili study Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Whither COVID-19 vaccines? Multisystem Inflammatory Syndrome in Children in the United States COVID-19 and multisystem inflammatory syndrome in children and adolescents Brighton Collaboration Working Group on A. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA. 2021. 25. Team CC-R, Food, Drug A. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material The Kigali modification of the berlin definition: a new epidemiological tool for ARDS? PALICC definition of ARDS. Don't remove that brick from the wall and keep it smart and simple Kawasaki disease and immunisation: Standardised case definition & guidelines for data collection Kawasaki disease: an essential comparison of coronary artery aneurysm criteria SARS-CoV-2-Related Inflammatory Multisystem Syndrome in Children: Different or Shared Etiology and Pathophysiology as Kawasaki Disease?